Cero Therapeutics Hldgs Inc.
13F holders, Q3 2024 (September 30)18holders +3
5new positions
1sold out
$0.09avg. 13F price*
At the end of Q3 2024, 18 institutions reported holding Cero Therapeutics Hldgs Inc. in their 13F filings, up 3 from Q2 2024. 5 opened new positions and 1 sold out. The largest holders were ARCH Venture Management, LLC ($135K), Avantax Planning Partners, Inc. ($127K) and Geode Capital Management, LLC ($15K).
- Company
- Cero Therapeutics Hldgs Inc.
- CUSIP
- 71902K105
- Latest filing quarter
- Q4 2024
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $20K |
| Exits | 1 | $5K |
All 13F filers, Q2 2024 → Q3 2024: 1,715,270 shares bought and 18,096 shares sold, net +1,697,174 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| ARCH Venture Management, LLC | 0.05% | No change | 1,444,296 | $135K |
| Avantax Planning Partners, Inc. | 0.00% | Add +1601.4% | 1,361,130 | $127K |
| Geode Capital Management, LLC | 0.00% | Add +227.0% | 157,445 | $15K |
| Selkirk Management LLC | 0.00% | New | 121,040 | $11K |
| HRT Financial LP | 0.00% | Add +566.6% | 79,562 | $7K |
| Fifth Lane Capital, LP | 0.02% | No change | 76,593 | $7K |
| Jane Street Group, LLC | 0.00% | Add +77.9% | 56,998 | $5K |
| XTX Topco Ltd | 0.00% | New | 56,532 | $5K |
| FNY Investment Advisers, LLC | 0.00% | Add +400.0% | 26,250 | $2K |
| StoneX Group Inc. | 0.00% | New | 16,600 | $2K |
| Corient Private Wealth LP | 0.00% | No change | 14,999 | $1K |
| Birchview Capital, LP | 0.00% | No change | 12,972 | $1K |
| Jump Financial, LLC | 0.00% | New | 11,948 | $1K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 4,965 | $462 |
| Osaic Holdings, Inc. | 0.00% | No change | 400 | $36 |
| Pineridge Advisors LLC | 0.00% | No change | 300 | $28 |
| Bank of America Corp. | 0.00% | Add +241.2% | 232 | $22 |
| JPMorgan Chase & Co. | 0.00% | No change | 2 | $0 |
"% of holder's portfolio" is CERO THERAPEUTICS HLDGS INC's weight in each manager's 13F, not the share of Cero Therapeutics Hldgs Inc. the manager owns.